By Lina carolina 
Glioblastoma, the most common and aggressive primary brain tumor, presents a formidable challenge in oncology, with a grim prognosis of less than two years of average survival post-diagnosis. Current treatment modalities have largely proven ineffective against this relentless disease. However, recent advancements in immunotherapy have offered a glimmer of hope for patients, though successes have been modest thus far. Now, a groundbreaking study from the University of Geneva (UNIGE) and Geneva University Hospitals (HUG) has unveiled a significant breakthrough: the identification of a specific surface marker on glioblastoma cells and the successful generation of CAR-T cells engineered to target and destroy these malignant cells. Crucially, these advanced immune cells appear to possess the remarkable ability to eliminate glioblastoma cells that do not express this identified marker, while sparing healthy brain tissue, a critical step towards safer and more effective therapies. The findings, published in the esteemed journal Cancer Immunology Research, mark a pivotal moment, paving the way for potential clinical trials in human patients.
The Intractable Nature of Glioblastoma
Glioblastoma tumors are characterized by a complex biological profile that renders them exceptionally difficult to treat. These tumors possess a remarkable ability to create a protective microenvironment, effectively shielding themselves from the body’s immune system and thwarting conventional therapies, leading to rapid recurrence. The infiltrative nature of glioblastomas, meaning they spread diffusely into surrounding brain tissue, makes complete surgical removal nearly impossible. This inherent invasiveness, coupled with their genetic heterogeneity, contributes to their notorious resistance to radiation and chemotherapy. For decades, the medical community has grappled with this devastating diagnosis, with limited progress in extending patient survival beyond incremental gains. The development of new strategies that can overcome these biological barriers has been a paramount objective.
A Novel Approach: CAR-T Cell Therapy Revolutionizes Cancer Treatment
Chimeric Antigen Receptor T-cell (CAR-T) therapy represents a paradigm shift in cancer treatment, particularly for hematological malignancies. This advanced form of immunotherapy involves genetically modifying a patient’s own T-cells, a type of white blood cell crucial for immune defense. In the laboratory, these T-cells are engineered to express chimeric antigen receptors (CARs) on their surface. These CARs are artificial receptors designed to recognize specific antigens – proteins or molecules – found on the surface of cancer cells. Once modified, these CAR-T cells are reinfused into the patient, where they act as highly targeted "living drugs," actively seeking out and destroying cancer cells bearing the recognized antigen. While CAR-T therapy has demonstrated remarkable success in treating certain blood cancers like B-cell lymphomas and acute lymphoblastic leukemia, its application in solid tumors, such as glioblastoma, has faced significant hurdles.
Identifying the Target: PTPRZ1 Emerges as a Key Marker
The research team, led by Denis Migliorini, assistant professor in the Department of Medicine at the UNIGE Faculty of Medicine, holder of the ISREC Foundation Chair in Brain Tumour Immunology, and a member of the Translational Research Centre in Onco-Haematology (CRTOH), has been diligently working to identify suitable target antigens on glioblastoma cells. Their persistent efforts have culminated in the identification of PTPRZ1 (Protein Tyrosine Phosphatase Receptor Type Z Polypeptide 1) as a particularly promising marker. PTPRZ1 is a transmembrane protein that is often overexpressed in glioblastoma and plays a role in tumor cell proliferation and survival.
"For several years, we have been trying to identify the protein markers expressed by glioblastoma cells," explains Professor Migliorini. "One of these markers, PTPRZ1, proved particularly important: we were able to generate CAR-T cells carrying antibodies targeting PTPRZ1. This is a first step towards CAR-T cells effective against malignant gliomas." This discovery is significant because it provides a specific molecular address for the engineered immune cells to home in on. The ability to target PTPRZ1 offers a potential avenue to disrupt glioblastoma’s survival mechanisms and initiate its destruction.
Overcoming Delivery Challenges: mRNA Technology for Brain Tumors
A critical challenge in developing CAR-T therapies for brain tumors lies in the delivery and persistence of the engineered cells. Traditional methods for generating CAR-T cells often employ viral vectors, which are highly efficient at introducing genetic material into cells. However, in the context of the brain, a delicate and complex organ, the long-term persistence of viral vectors can raise concerns about potential toxicity.
"Most CAR-T cells are generated using viral vectors, a technique that has proved its worth in certain diseases but is not very suitable in the brain," states Darel Martinez Bedoya, a post-doctoral fellow in Professor Migliorini’s laboratory and the first author of this research. "Indeed, they persist for a very long time in the context of blood cancers. The brain is a fragile organ, and this persistence can generate a risk of toxicity."
To circumvent these risks, the Geneva team adopted an innovative approach using messenger RNA (mRNA). Instead of permanently integrating viral DNA, they introduced mRNA encoding for the desired antibody into the T-cells. The cell’s own machinery then utilizes this mRNA to produce the specific protein that forms the CAR receptor on the T-cell surface, enabling it to recognize the tumor target. This mRNA-based strategy offers several distinct advantages for brain tumor therapy.
The Advantages of mRNA-Based CAR-T Cells
The mRNA approach provides a more transient and controllable method for CAR-T cell generation. This transient nature is particularly beneficial for brain tumors, where minimizing off-target effects and long-term toxicity is paramount.
"This technique has a number of advantages: CAR-Ts offer a flexible platform, allowing multiple adaptations according to the specificities and evolution of the tumour," explains Mr. Martinez Bedoya. The flexibility of mRNA technology means that CAR-T cells can be quickly re-engineered or modified if the tumor develops resistance or if new therapeutic targets emerge. This adaptability is crucial in the fight against glioblastoma, a disease known for its rapid evolution and propensity to develop resistance mechanisms. Furthermore, mRNA-based therapies are generally considered safer than viral vector approaches due to their transient expression, reducing the risk of insertional mutagenesis or chronic inflammation in the sensitive brain environment.
Demonstrating Efficacy and Safety: In Vitro and In Vivo Success
The researchers meticulously evaluated the efficacy and safety of their PTPRZ1-targeting CAR-T cells. The initial phase of testing involved in vitro experiments, where the CAR-T cells were co-cultured with both healthy human brain cells and glioblastoma cells.
"To our surprise, not only did CAR-Ts not attack healthy cells, but they were also capable, by bystander effect, of identifying and fighting tumour cells not expressing the PTPRZ1 marker," Professor Migliorini reports with evident satisfaction. This "bystander effect" is a critical finding. It suggests that even if not all glioblastoma cells within a tumor express the PTPRZ1 marker, the CAR-T cells can still eliminate them. This phenomenon is attributed to the release of pro-inflammatory molecules by the CAR-T cells, which can kill neighboring tumor cells even if they don’t directly express the target antigen. This "bystander effect" significantly broadens the therapeutic potential of the CAR-T cells, addressing the heterogeneity often seen in glioblastoma.
The second, more advanced stage of the study involved in vivo testing in mouse models engineered to develop human glioblastoma. These experiments provided crucial insights into the therapeutic efficacy and safety profile of the CAR-T cell therapy in a living organism.
Controlling Tumor Growth and Extending Survival in Mouse Models
In the preclinical mouse models, the administration of the PTPRZ1-targeting CAR-T cells resulted in significant control of glioblastoma tumor growth. More importantly, the treatment led to a remarkable prolongation of survival in the treated mice, with no observable signs of toxicity. The researchers administered the CAR-T cells intratumorally, directly into the central nervous system (CNS). This localized delivery strategy offers several advantages for brain tumor treatment.
"By administering CAR-Ts intratumourally in the CNS, we can use fewer cells and greatly reduce the risk of peripheral toxicity," the scientists explain. Direct administration into the CNS allows for higher concentrations of the therapeutic cells at the tumor site while minimizing systemic exposure and potential side effects in other organs. This targeted approach is particularly important for therapies intended for brain tumors, where the blood-brain barrier can impede the penetration of systemically administered drugs.
The Road Ahead: Towards Clinical Trials and Future Implications
The compelling results from both in vitro and in vivo studies have provided a strong foundation for the advancement of this novel CAR-T cell therapy. The successful demonstration of efficacy, safety, and the crucial bystander effect in preclinical models has emboldened the research team to pursue clinical translation.
"With this data and other unpublished yet, all lights are green to now envisage a first clinical trial in humans," the scientists conclude, signaling a significant step forward in the fight against glioblastoma. The transition from laboratory research to human clinical trials is a complex and rigorously regulated process. However, the promising nature of this CAR-T therapy, particularly its innovative mRNA-based approach and demonstrated ability to overcome tumor heterogeneity, positions it as a strong candidate for further investigation.
Broader Impact and Future Directions
The implications of this research extend beyond the immediate treatment of glioblastoma. The development of a safe and effective mRNA-based CAR-T cell platform for brain tumors could pave the way for similar therapies targeting other challenging CNS malignancies. Furthermore, the understanding gained about the PTPRZ1 marker and the bystander effect could inform the development of new therapeutic strategies for a range of cancers.
The journey of glioblastoma treatment has been arduous, marked by persistent challenges. However, the innovative work undertaken by the UNIGE and HUG teams offers a beacon of hope. By combining cutting-edge CAR-T cell technology with novel mRNA delivery methods and identifying a critical tumor marker, these researchers have made a significant stride. While the path to widespread clinical application will undoubtedly involve further rigorous testing and validation, this breakthrough represents a crucial step towards a future where glioblastoma patients may have access to more effective and less toxic treatment options. The successful translation of this research into human trials could mark a turning point in the long and difficult battle against this devastating brain cancer.
